An association between the R990G polymorphism of the CaSR gene, coding for calcium-sensing receptor, and primary hypercalciuria was found in kidney stone formers. To confirm this relationship, we investigated hypercalciuric women without stones and studied the effect of CaSR gene in human embryonic kidney cells (HEK-293). We genotyped for CaSR A986S, R990G, and Q1011E polymorphisms, 119 normocalciuric and 124 hypercalciuric women with negative history of kidney stones. Homozygous (n ¼ 2) or heterozygous (n ¼ 21) women for the 990G allele considered as one group had an increased risk to be hypercalciuric (odds ratio ¼ 5.2; P ¼ 0.001) and higher calcium excretion (P ¼ 0.005) in comparison with homozygous women for the 990R allele (n ¼ 220). HEK-293 cells were transfected with the variant allele at the three CaSR gene polymorphisms and with the most common allele with no variants. The transient increment of intracellular calcium caused by the stepwise increase of extracellular calcium was evaluated in stable transfected cells loaded with fura-2 AM. The extracellular calcium concentration producing the half-maximal intracellular calcium response was lower in HEK-293 cells transfected with the 990G allele than in those transfected with the wild-type allele (P ¼ 0.0001). Our findings indicate that R990G polymorphism results in a gain-of-function of the calcium-sensing receptor and increased susceptibility to primary hypercalciuria.
An association between the R990G polymorphism of the CaSR gene, coding for calcium-sensing receptor, and primary hypercalciuria was found in kidney stone formers. To confirm this relationship, we investigated hypercalciuric women without stones and studied the effect of CaSR gene in human embryonic kidney cells (HEK-293). We genotyped for CaSR A986S, R990G, and Q1011E polymorphisms, 119 normocalciuric and 124 hypercalciuric women with negative history of kidney stones. Homozygous (n ¼ 2) or heterozygous (n ¼ 21) women for the 990G allele considered as one group had an increased risk to be hypercalciuric (odds ratio ¼ 5.2; P ¼ 0.001) and higher calcium excretion (P ¼ 0.005) in comparison with homozygous women for the 990R allele (n ¼ 220). HEK-293 cells were transfected with the variant allele at the three CaSR gene polymorphisms and with the most common allele with no variants. The transient increment of intracellular calcium caused by the stepwise increase of extracellular calcium was evaluated in stable transfected cells loaded with fura-2 AM. The extracellular calcium concentration producing the half-maximal intracellular calcium response was lower in HEK-293 cells transfected with the 990G allele than in those transfected with the wild-type allele (P ¼ 0.0001). Our findings indicate that R990G polymorphism results in a gain-of-function of the calcium-sensing receptor and increased susceptibility to primary hypercalciuria.
The calcium-sensing receptor (CaSR) is a G-protein-coupled membrane receptor that allows parathyroid and kidney tubular cells to regulate parathyroid hormone (PTH) secretion and tubular calcium reabsorption according to the plasma calcium concentration. [1] [2] [3] The CaSR molecule comprises a large extracellular domain, a transmembrane domain, and an intracellular tail. 3 Calcium binding to the extracellular domain stimulates the interaction of transmembrane and intracellular domains with G-proteins and activates a complex network of intracellular messengers, leading to phospholipase C-dependent inositol 1,4,5-triphosphate production and thus calcium release from intracellular stores as self-maintained low-frequency repetitive calcium spikes. 4, 5 Through this cascade of events, CaSR activation inhibits PTH secretion and calcium reabsorption in the thick ascending limb. 6, 7 Thus, CaSR activation increases urinary calcium excretion by both a direct and a PTH-mediated effect on kidney tubular cells. In cultured dog kidney distal tubular cells, CaSR inhibits active calcium reabsorption through an inhibition of calcium pump. 8 It also inhibits passive calcium reabsorption in the thick ascending limb, where it decreases sodium-chloride-potassium cotransport activity and, thus, the lumen-interstitium electric potential driving passive paracellular calcium reabsorption. 7, 9 In addition to parathyroid and kidney cells, CaSR is also expressed in many other calcium-handling cells, such as osteoblasts and enterocytes. 10, 11 However, the contribution of CaSR to the regulation of bone remodeling and intestinal calcium absorption still remains unclear.
In agreement with these findings, high urinary calcium excretion and hypocalcemia characterize the phenotype of individuals bearing activating mutations of the CaSR gene, 12 whereas hypocalciuria and hypercalcemia characterize patients with CaSR-inactivating mutations. 13 Three single nucleotide polymorphisms (SNPs) of CaSR gene have been mapped on the portion of exon 7 coding for the CaSR intracellular tail. In Caucasians, Ala986Ser (A986S, base change 2956G4T) is the most frequent among these SNPs. The 986S variant allele was associated with higher plasma calcium concentrations, although within the normal range. 14, 15 High plasma calcium concentrations have also been reported in patients with the less-frequent SNP Gln1011Glu (Q1011E, base change 3031C4G). 15 On the contrary, the Arg990Gly SNP (R990G, base change 2968A4G) was associated with primary hypercalciuria, as the 990G variant allele was more frequent in hypercalciuric calcium stone-forming patients, compared with normocalciuric stone formers or healthy individuals. 16 Furthermore, the 990G variant allele was associated with slightly lower plasma concentrations of ionized calcium in healthy individuals 15 and with lower levels of circulating PTH in patients with primary or secondary hyperparathyroidism. 17, 18 Primary hypercalciuria is characterized by high calcium excretion in the presence of normal plasma calcium concentrations. 19 The prevalence of primary hypercalciuria is approximately 10% in the general population, whereas it is 40-50% among calcium kidney stone formers 19 and approximately 20% among osteoporotic women. 20 The family clustering of primary hypercalciuria suggests that the genetic determination of the trait is characterized by a polygenic background. 21, 22 CaSR could contribute to this genetic background and its R990G SNP increase susceptibility to primary hypercalciuria in stone-forming patients. 16 To assess this finding in individuals without stones, the primary goal of this work was to test the distribution of the 990G allele in hypercalciuric women without kidney stones recruited among women referred to the Osteoporosis Outpatient Clinics of two Northern-Italy Hospitals. Our hypothesis was that the 990G allele might enhance CaSR function, which could directly inhibit calcium reabsorption in the distal tubule. Therefore, we also tested the functional effects of the CaSR 990G, 986S, and 1011E alleles, and of the most common allele with no variants in human embryonic kidney cells (HEK-293). As HEK-293 cells do not express an endogenous CaSR, we transfected them with the CaSR gene and compared the effect of the different alleles.
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RESULTS
CaSR haplotypes in hypercalciuric and normocalciuric women
Allele distribution respected Hardy-Weinberg equilibrium for each CaSR SNP in the whole population (comparison between expected and observed distribution: P ¼ 0.99, P ¼ 0.20, and P ¼ 0.91 for A986S, R990G, and Q1011E, respectively). A986S was the most recurrent SNP in our population. Frequency of the 990G variant allele was higher in hypercalciuric than normocalciuric women (Figure 1a ). This finding underwent 10 000 permutations with Haploview 3.02 and remained highly significant. Linkage disequilibrium between the investigated SNPs was very poor (Table 1) .
Four haplotypes were identified in our population and characterized by no or one single variant allele at the investigated SNPs (Table 2 ). Only n ¼ 5 women were double heterozygotes at the A986S and R990G SNPs, and it was impossible to reconstruct their haplotype because of the low SNP frequency. Haplotype ARQ (no variant allele) was the most frequent. Haplotype AGQ, having the 990G variant allele, was significantly associated with hypercalciuria ( Figure 1b) .
According to allele frequency, genotype distribution at the R990G SNP was different in hypercalciuric and normocalciuric women (Figure 1c) 
CaSR expression in transfected HEK-293 cells
To test if the selected clones expressed the same level of CaSR, we performed Western blot analysis. CaSR expression was tested on immunoblots stained with anti-human CaSR monoclonal antibody to detect total CaSR-immunoreactive species in transfected HEK-293 cells. Under reducing condition, the antibody detected three major bands of 250 kDa (dimeric form), 130 kDa (monomeric receptor), and 150 kDa (glycosylated monomeric receptor). 27, 28 All transfected cells showed comparable immunoreactive CaSR expression, whereas HEK-vector cells did not show any band ( Figure 4 ).
Prediction of CaSR secondary structure
The protein structure prediction server method predicted that substitution of arginine with glycine in the CaSR aminoacid sequence at position 990 caused a break in the a-helix between codons 984 and 997, thus substantially modifying the secondary structure of the CaSR intracellular tail. Prediction confidence provided by the method was between 50 and 75%. 29 
DISCUSSION
In a previous paper from our group, we found that the R990G SNP of the CaSR gene was associated with primary hypercalciuria in stone-forming patients. 16 We now confirm that the 990G allele is associated with primary hypercalciuria in women without kidney stones, in agreement with in vitro findings showing that the 990G allele results in a CaSR gain of function. The association between the R990G SNP and hypercalciuria appeared independent from kidney stone disease, although a strong relationship between calcium excretion and predisposition to stone production is acknowledged. 30 We analyzed the in vitro CaSR activity in transfected HEK-293 cells as the capability to release calcium ions from intracellular stores in response to an increase in extracellular calcium concentration, a pathway dependent on phospholipase C activation and inositol 1,4,5-triphosphate production. 3 Table 1 . Risk to be hypercalciuric was increased in women bearing haplotype GGC (characterized by variant allele only at the R990G SNP) and was calculated by logistic regression with haplotype GAC (women with no variant alleles) as reference group. Frequency of haplotype is indicated at the summit of each column. (c) Distribution of genotype at the R990G SNP in normocalciuric and hypercalciuric women. The distribution was different in hypercalciuric and normocalciuric women with an increased risk to be hypercalciuric in homozygotes or heterozygotes for the rarer 990G allele (n ¼ 23) compared with the homozygous women for the 990R allele (n ¼ 220). Haplotype ARQ is the most frequent haplotype and may be considered as the 'wild-type' sequence (no variant allele at studied SNPs). SRQ, AGQ, and ARE were characterized by the presence of one variant allele at the A986S, R990G, and Q1011E SNPs, respectively. Only five women were double heterozygotes at the A986S and R990G SNPs. These women were excluded from the haplotype analysis, because their haplotype could not be reconstructed due to low frequency of each SNP in the population sample. Haplotypes were identified by the aminoacid coded at the three studied polymorphic loci. Base and aminoacid changes are displayed for each SNP. The association of higher calcium excretion with the 990G allele was observed in patients with primary hyperparathyroidism, where a correlation of this allele with kidney stones was also reported, confirming the role of excreted calcium in stones formation. 17, 30, 32 Before the present study, the only article on functional effects of exon 7 SNPs did not find any change in CaSR activity in HEK-293 cells transfected for the 990G allele. 33 Different experimental procedures might explain this discrepancy; however, how experimental differences may impact CaSR activity remains unexplained.
An activated CaSR response to extracellular calcium may predispose to hypercalciuria through a greater inhibition of calcium reabsorption in the ascending limb cells in which CaSR is expressed on basolateral plasma membrane. 7 The relative rarity of the 990G variant allele agrees well with the low frequency of hypercalciuria of renal origin. However, renal hypercalciuria has been mainly studied in stoneforming patients 34 as few studies have analyzed hypercalciuria determinants in stone-free individuals. 35 CaSR is also expressed in enterocytes and osteoblasts and changes of activity in hypercalciuria are likely to affect calcium metabolism also in bones and intestine, although we can only assess the effect of those changes in the kidney. 10, 11 No other causes of hypercalciuria were evident in women bearing the 990G allele. In particular, vitamin D stores were not different in women with different genotype and were not related to vitamin D supplementation or with plasma concentrations of calcium or PTH.
In women bearing the 990G variant allele, the increase in calcium excretion was not coupled with a decrease in plasma concentrations of calcium and PTH. Accordingly, previous works reported a significant decrease only in plasma-ionized calcium concentrations, which were not measured in our patients. 15 In studies in patients with primary hyperparathyroidism and in uremic patients with secondary hyperparathyroidism, lower plasma PTH concentrations were instead associated with the 990G allele. 17, 18 The lack of a clear association between the CaSR 990G allele and PTH production or plasma calcium concentration, suggests that this allele could influence PTH secretion less markedly than tubular calcium reabsorption, or that other variables, like intestinal calcium absorption and dietary calcium intake, may limit the effect of 990G on PTH secretion and circulating calcium.
The neutral amino-acid glycine substituting the basic amino-acid arginine at residue 990, changes the local electric charge distribution on intracellular domain of CaSR. Moreover, glycine allows a wider rotation angle of the a-helix in the protein secondary structure than amino acids with longer lateral chains as arginine. 36 Therefore, it is likely that glycine 990 changes the spatial conformation and folding of the CaSR intracellular domain, altering the capability of CaSR to activate G proteins or to bind filamin-A. The adopted Jones' model indicated that glycine 990 causes a break in the ahelix. 29 The spatial modification of CaSR intracellular tail may modify its efficiency in activating G protein and, thus, phospholipase C, A, or D. 37 These intracellular signaling pathways seem differently involved in the regulation of parathyroid secretion or kidney calcium reabsorption. CaSRstimulated phospholipase C activity inhibits PTH secretion through inositol-1,4,5-triphosphate production and calcium mobilization from intracellular stores. Stimulation of phospholipase A to produce 20-hydroxyeicosatetraenoic acid inhibits sodium and calcium reabsorption in thick ascending limb of the Henle loop. 7, 39 Because it is expressed in intracellular tail, the R990G SNP might activate phospholipase A or C to a different degree, thus influencing PTH secretion less markedly than tubular calcium reabsorption. 4, 7 This different degree of activation of phospholipase A or C could explain the lack of hypocalcemia in individuals bearing the 990G allele. The intracellular tail also interacts with filamin-A, a protein anchoring CaSR to caveolae in parathyroid cells and functioning as a scaffolding protein to maintain signaling activity of CaSR at an optimal level. 38 The binding site of CaSR to filamin A includes the amino acids between positions 907 and 997, thus comprising residue 990. 38 In conclusion, a conformational change caused by the R990G SNP in the intracellular domain may be responsible of a CaSR gain of function that modulates CaSR interaction with G proteins or filamin A, increasing individual susceptibility to primary hypercalciuria.
MATERIALS AND METHODS Patients
One hundred and nineteen normocalciuric (age ¼ 6371.0 years, body weight ¼ 6270.9 kg, urinary calcium excretion ¼ 3.457 0.122 mmol per 24 h) and 124 hypercalciuric women (age ¼ 6070.8 Women were eligible for the study if they were Caucasian, had no personal history of kidney stones, and had normal plasma creatinine and calcium concentrations. Women were included regardless of their bone mineral density values, none had diseases other than osteoporosis. No participants have been taking antifracture drugs or drugs affecting calcium excretion (thiazide, bisphosphonate, vitamin D, calcium, or others) in the 3 months preceding their inclusion in the study. Plasma concentrations of calcium and creatinine and 24-h urinary calcium excretion were measured in all participants using standard methods. Serum intact PTH was measured by immunoradiometric assays (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Plasma 25-hydroxyvitamin D was measured by radioimmunoassay method (Diasorin, Stillwater, MN, USA).
The study complies with the Declaration of Helsinki Principles and was approved by the San Raffaele Hospital Ethical Committee. All participants signed an informed consent, which included consent for genetic testing.
Genotyping
Genomic DNA was isolated from peripheral blood cells by standard procedures. The part of exon 7 of CaSR gene, comprising three nonconservative SNPs (G/T at codon 986, A/G at codon 990 and C/G at codon 1011), was evaluated by polymerase chain reaction amplification and direct sequencing. Polymerase chain reaction was carried out using primers 5 0 -CAGAAGGTCATCTTTGGCAGCGG CA-3 0 and 5 0 -TGCAGACCTGTTTCCTGGACGGTC-3 0 , as described previously. 16 Site-directed mutagenesis of the human CaSR and stable receptor expression The human CaSR cDNA, cloned in pCR3.1 plasmid (Invitrogen, Carlsbad, CA, USA), was kindly provided by Dr Jianxin Hu (NIH, Bethesda, MD, USA). The plasmid checked by sequencing was found to bear the 990G allele (haplotype AGQ). Separate point mutations were performed to produce CaSR containing 986S, 990R, or 1011E allele, respectively. Site-directed mutagenesis was directly performed on CaSR-plasmid using Gene Tailor Mutagenesis System (Invitrogen), according to the manufacturer's instructions. The mutations were produced by polymerase chain reaction amplification using a couple of overlapping primers for each mutant, only one containing the target mutation site ( Table 4 ). The Platinum Taq DNA Polymerase High Fidelity (Invitrogen) was used for 20 cycles amplification, according to Gene Tailor Mutagenesis System procedure. Mutant plasmids were amplified in Escherichia coli, DH-5a strain, and DNA was extracted with the alkaline lysis procedure. The sequence of mutant receptor was confirmed by automated DNA sequencing of entire CaSR complementary DNA on ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, CA, USA).
Human embryonic kidney cells (HEK-293; Cell Bank, IST, Genoa, Italy) were grown in Dulbecco's modified Eagle's medium (Sigma Chemicals, St Louis, MO, USA), supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin under standard condition (5% CO 2 , 371C). Each 75 cm 2 flask of 80-90% confluent HEK-293 cells were transfected with 24 mg plasmid DNA, using LipofectAMINE 2000 (Invitrogen).
Stable clone selection began 48 h after the start of transfection in medium with 1 mg/ml geneticin (Sigma Chemicals). The clones were available in 1-2 weeks and cultured routinely. Resistant colonies were subcloned and screened for CaSR expression with Western blot analysis. The selected clones (HEK-wt, HEK-990G, HEK-986S and HEK-1011E cells) expressed similar levels of CaSR protein, whereas no expression was found in cells transfected with empty plasmid (HEK-vector; Figure 4 ).
Western blotting
Stable transfected cells were trypsinized and the pellet was lysed with ice-cold lysis buffer (150 mmol/l NaCl, 10 mmol/l Tris-HCl pH 7.2, 0.1% sodium dodecyl sulfate, 1% TritonX-100, 1% deoxycholate, 5 mmol/l ethylenediaminetetraacetic acid, 1 mmol/l phenylmethylsulfonyl fluoride, 10 mmol/l benzamidine, 2 mg/ml leupeptin, and 0.1 mmol/l Na-orthovanadate). The extracts were forced through a 22-gauge needle 5-8 times, the lysate was centrifuged at 15 000 r.p.m. for 10 min at 41C and the supernatant was collected and stored at À801C. Protein concentration was assayed using Bradford reagent (Sigma Chemicals). Samples (5 mg proteins per well) were denatured with denaturing buffer: 7 mol/l urea, 2 mol/l thiourea, 65 mmol/l dithiothreitol, 5 Â laemmli sample buffer (final concentration 2% sodium dodecyl sulfate) for 30 min at room temperature. Iodoacetamide (130 mmol/l) was added to block dithiothreitol for 30 min at room temperature. Proteins were separated on 8% laemmli gel and then electrotransferred to polyvinylidene difluoride membrane at 400 mA for 1 h. The blots were blocked in a blocking solution (5% milk in Tris-buffered saline Tween) and then incubated for 2 h at at room temperature with 0.2 mg/ml monoclonal anti-CaSR antibody (average daily dose, against residues 214-235 of the human CaSR protein (AffinityBioreagents, Golden, CO, USA)). Then, membranes were incubated in the blocking solution with secondary horseradish peroxidase-coupled anti-mouse IgG (Jackson ImmunoResearch Laboratories, Suffolk, UK) at a 1:10000 dilution for 1 h at room temperature. The same membranes were incubated with polyclonal anti-b-actin antibody (Sigma Chemicals), overnight at 41C with a 1:1000 dilution. This primary antibody was revealed with secondary horseradish peroxidase-coupled anti-rabbit IgG (Amersham Biosciences, Little Chalfont, UK) with a 1:5000 dilution for 1 h at at room temperature. Specific protein bands were detected using SuperSignal West Pico enhanced chemiluminescence system (Pierce, Rockford, IL, USA).
5 cells/ml of HEK-293 were used for each experiment. Cells were suspended in a bath solution (123 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgCl 2 , 10 mmol/l glucose, 25 mmol/l N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid, 0.5 mmol/l CaCl 2 , pH 7.4, at 371C, 285 mOsm/l) and loaded with fura-2 AM (1 mmol/l, Sigma Chemicals), at 371C for 45 min. After incubation, cells were washed with the bath solution and the same cell concentration was transferred into a thermostatted quartz cuvette containing the bath solution. [Ca 2 þ ] o was increased stepwise by adding CaCl 2 to the bath solution to reach calcium concentration of 0.9, 1.5, 2.3, 3.3, 5.3, 7.3, 9.3, and 11.3 mmol/l in the assay medium. 23 The fluorescence measurements were carried out as described previously. 24, 25 Transient responses of [Ca 2 þ ] i were normalized according to Pearce et al. 23 Briefly, the size of the peak of the transient [Ca 2 þ ] i in response to each tested [Ca 2 þ ] o stimulus was summed to the size of the previous individual peaks and expressed as the proportion of the total peak counts for the full concentration-response curve. EC 50 value was calculated in each individual experiments.
CaSR secondary-structure prediction The correlation between CaSR secondary structure type and the substitution of arginine with glycine at the position 990 was predicted according to the Jones' criteria. 34 We applied the prediction method PSIPRED (protein structure prediction server) for protein sequence analysis, 29 available on server 'Predict Protein' (http://cubic.bioc.columbia.edu/ predictprotein/).
Statistical analysis
Distribution of CaSR alleles, haplotypes, or genotypes was compared in normocalciuric and hypercalciuric women by w 2 test or multivariable logistic regression. Relative risk to be hypercalciuric was estimated by calculating the odds ratio and 95% confidence interval. Quantitative variables were reported as mean7s.e. Differences between means were tested by Student's t-test or one-way analysis of variance. Sheffè post hoc test was used to compare results in transfected cells. Dependence of calcium excretion on CaSR genotypes was evaluated by stepwise multiple regression analysis. Statistical analysis was performed using the SPSS 10 statistical package. Linkage disequilibrium between SNPs was tested measuring D 0 and LOD score using Haploview 3.32 software (http:// www.broad.mit.edu/mpg/haploview/). 40 The same software was adopted for haplotype reconstruction and to submit allele distribution findings to permutation procedure (number of permutations ¼ 10 000).
As our primary goal was to test the association of the R990G SNP with hypercalciuria, statistical analysis was conducted at the a ¼ 0.05 level and was two-tailed. For this a level, the power to test the association of allele at the R990G SNP with hypercalciuria was calculated with the 'PAWE' software (http://linkage.rockefeller.edu/ pawe/pawe.cgi) and was 92.3%. 41 
